China’s ‘Moutai of funeral services’ posts first loss in a decade as consumers stay cautious


China’s largest cemetery operator and funeral services provider, Fu Shou Yuan, reported its first loss in more than a decade, becoming the latest casualty of sluggish consumer spending in the country.

For the first six months of this year, the 31-year-old Shanghai-based company posted a net loss of 261 million yuan (US$36.6 million), its first loss since 2010, according to interim results released on Friday.

Total revenue plunged 44.5 per cent to 610.9 million yuan. Revenue from burial services, primarily involving the sale of burial plots, fell 47 per cent to 477 million yuan, while funeral services experienced a 34 per cent decline, totalling 122 million yuan.

The company attributed its struggles to various external challenges that had dampened consumer demand. “In this economic environment, customers seem to be more cautious in their spending on death care services, while competition within the industry has shown signs of intensifying,” it said.

Despite previously enjoying double-digit growth in China – home to a vast and rapidly ageing population – Fu Shou Yuan’s leading position in the industry is under pressure. Often referred to as the “Moutai of funeral services” – a tongue-in-cheek nod to the country’s most valuable liquor brand – the company faces increasing difficulty in maintaining growth.
The Babaoshan cemetery in Beijing. Photo: AP
The Babaoshan cemetery in Beijing. Photo: AP

Fu Shou Yuan initially experienced a surge in business after China lifted its strict Covid-19 restrictions in late 2022. In the first half of 2023, net profit jumped 78 per cent to 464.7 million yuan, driven by soaring burial plot prices, particularly in major cities like Beijing and Shanghai, where prices sometimes increased at a rate faster than residential properties.

  • Related Posts

    Lean harder into Hong Kong-mainland China market ties, ‘two sessions’ delegates urge

    Hong Kong can reinforce its role as an international financial centre by deepening integration with mainland capital markets and expanding cross-border investment channels, financial industry leaders said on Thursday during…

    Continue reading
    Insilico Medicine advances Middle East push with UAE AI drug discovery deal

    Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates’ drug regulator to advance the use of its artificial intelligence tools in drug discovery across the…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *